This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease

This study has been completed.
Immunex Corporation
Information provided by (Responsible Party):
University of Wisconsin, Madison Identifier:
First received: September 13, 2005
Last updated: October 25, 2016
Last verified: September 2005
This pilot study will investigate the safety and effect of etanercept in HIV infection by studying HIV replication and immune function (as measured by CD4 counts) in individuals with HIV infection.

Condition Intervention
HIV Infections Drug: etanercept

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: A Pilot Study to Examine the Feasibility and Effect on Tumor Necrosis Factor (TNF) Inhibition on HIV Disease

Resource links provided by NLM:

Further study details as provided by University of Wisconsin, Madison:

Primary Outcome Measures:
  • changes in CD4 counts
  • changes in HIV-RNA levels

Secondary Outcome Measures:
  • development of infections
  • degree of TNF inhibition by measuring TNF levels
  • changes in hematologic and biochemical laboratory tests

Enrollment: 25
Study Start Date: May 2002
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults greater than 18 years of age with documented HIV infection
  • Highly active antiretroviral therapy (HAART) regimens as defined by the Department of Health and Human Services guidelines; stable regimens for 12 weeks.
  • CD4 greater than 200 at time of study enrollment
  • Stable monitoring labs (hematology survey with differential, ALT, creatinine)
  • Absolute neutrophil count within normal limits

Exclusion Criteria:

  • AIDS defining illness within the last 6 months
  • Acute bacterial, viral, or fungal infection within the last 1 month, or history of recurring infections
  • Women who are pregnant or nursing
  • Hypersensitivity to etanercept
  • Previous use of etanercept
  • Acute malignancy in the last 5 years excluding in situ cervical cancer (CA) and common skin cancers (non melanoma)
  • History of active or latent tuberculosis
  • History of demyelinating nerve disease
  • History of seizure disorder
  • Latex allergy
  • Subject has any of the following laboratory values within 30 days of baseline:

    • hemoglobin concentration < 10.0 g/dl for men and < 9.0 g/dl for women
    • platelet count < 75,000/mm3
    • AST or ALT > 5x upper limit of normal (ULN)
    • serum creatinine > 2.5x ULN
    • serum pancreatic amylase > 1.5 ULN
  • Subject requiring treatment with immunomodulating agents, such as systemic corticosteroids, interleukins, vaccines, or interferon
  • Subjects who chronically use any over-the-counter (OTC) or prescription medication (except vitamins) must not change the regimen or switch their medication within 3 days of drug administration and until discharged from the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00205231

United States, Wisconsin
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
Immunex Corporation
Principal Investigator: Andrew Urban, MD University of Wisconsin, Madison
  More Information

Responsible Party: University of Wisconsin, Madison Identifier: NCT00205231     History of Changes
Other Study ID Numbers: 2001-557
Study First Received: September 13, 2005
Last Updated: October 25, 2016

Keywords provided by University of Wisconsin, Madison:

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Pathologic Processes
Slow Virus Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gastrointestinal Agents
Immunosuppressive Agents
Immunologic Factors processed this record on September 21, 2017